Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in relapsed multiple myeloma
NL-OMON38264Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Panobinostat + bortezomib + dexamethasone with Placebo + bortezomib + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Oct 2010; status: recruiting.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON38264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38264.